Bacterial Meningitis
An acute, life-threatening bacterial infection of the brain and spinal cord membranes presenting with fever, headache, and stiff neck, requiring emergent antibiotic treatment.
Emergency Management: Septic shock with purpura fulminans (Waterhouse-Friderichsen syndrome) requiring massive fluid resuscitation, vasopressors, and ICU support. Brain herniation requiring hyperosmolar therapy (Mannitol 1 g/kg IV or hypertonic saline) and intubation with hyperventilation.
Bacterial meningitis is a life-threatening, acute purulent infection of the pia mater, the arachnoid mater, and the subarachnoid space (the meninges). It is characterized by intense inflammation of the central nervous system driven by bacterial invasion. Rapid intervention is required as the disease can rapidly progress to cerebral edema, increased intracranial pressure, brain herniation, and death.
Detailed Overview
The classic triad of symptoms includes fever, nuchal rigidity (stiff neck), and altered mental status, though all three are present in less than 50% of adult cases. The most common causative organisms vary by age, with Streptococcus pneumoniae and Neisseria meningitidis predominating in adults. Diagnosis hinges on prompt lumbar puncture for cerebrospinal fluid (CSF) analysis, demonstrating neutrophilic pleocytosis, low glucose, and high protein. Given the high mortality rate and potential for severe neurological sequelae (e.g., hearing loss, cognitive impairment), empirical broad-spectrum antibiotics and adjunctive corticosteroids must be administered immediately upon suspicion, even before CSF results are obtained.
Epidemiology & Demographics
In the United States, the incidence is approximately 1-2 cases per 100,000 population annually. Rates are highest in infants <1 year of age. Neisseria meningitidis outbreaks occasionally occur in crowded settings such as college dormitories and military barracks. Mortality ranges from 10% to 20% despite appropriate antimicrobial therapy.
Etiological Mechanism
Common pathogens vary by age group. Neonates (<1 month): Streptococcus agalactiae (Group B Strep), Escherichia coli, Listeria monocytogenes. Children & Adults: Streptococcus pneumoniae, Neisseria meningitidis. Older adults (>50 years) and immunocompromised: S. pneumoniae, N. meningitidis, L. monocytogenes.
Primary Causes
Direct bacterial invasion of the subarachnoid space. This usually occurs via hematogenous spread following nasopharyngeal colonization, or less commonly, through direct spread from contiguous infections (e.g., otitis media, sinusitis) or penetrating head trauma.
Pathogens colonize the nasopharynx, evade host mucosal defenses (e.g., via IgA proteases), and enter the bloodstream. They cross the blood-brain barrier via tight junctions of the choroid plexus or cerebral capillaries. Within the subarachnoid space, rapid bacterial multiplication occurs due to poor localized humoral immunity. Bacterial lysis (spontaneous or antibiotic-induced) releases potent inflammatory mediators (teichoic acid, lipopolysaccharide), triggering a massive cascade of cytokines (TNF-alpha, IL-1). This results in increased blood-brain barrier permeability, vasogenic edema, loss of cerebral autoregulation, and significantly increased intracranial pressure (ICP), ultimately leading to neuronal ischemia and injury.
Diagnostic Criteria & Guidelines
Diagnosis is confirmed by Lumbar Puncture (LP) showing typical CSF characteristics and positive Gram stain or culture. A CT head prior to LP is indicated only if there are papilledema, focal neurologic deficits, altered mental status, immunocompromise, or a history of CNS disease. Empiric therapy should NOT be delayed for neuroimaging.
Immediate empiric therapy for adults: Ceftriaxone 2 g IV q12h (or Cefotaxime 2 g IV q4h) + Vancomycin 15-20 mg/kg IV q8-12h. For adults >50 years or immunocompromised, add Ampicillin 2 g IV q4h to cover Listeria. Dexamethasone 0.15 mg/kg IV q6h should be administered 15-20 minutes BEFORE or WITH the first dose of antibiotics (proven to reduce mortality and hearing loss in pneumococcal meningitis).
Second-Line & Adjunctive Therapy
Targeted therapy based on culture/susceptibilities. For penicillin-allergic patients (severe): Meropenem 2 g IV q8h + Vancomycin. For Listeria in penicillin-allergic patients: Trimethoprim-sulfamethoxazole 5 mg/kg IV q6h.
Surgical & Procedural Management
Rarely required unless there is a complication such as a subdural empyema, brain abscess requiring drainage, or severe hydrocephalus necessitating an external ventricular drain (EVD).
Patient Counseling & Advice
Inform patients and families that bacterial meningitis is a life-threatening emergency. Discuss the potential for long-term neurological sequelae, including hearing loss and cognitive deficits. Close contacts may require chemoprophylaxis if the pathogen is Neisseria meningitidis or Haemophilus influenzae type b.
Follow-Up & Monitoring Schedule
Neurological examination and audiometry. Monitor for delayed complications such as hydrocephalus. Ensure appropriate vaccinations post-recovery, especially assessing for immune deficiencies if recurrent.
Preventive Strategies
Vaccination is the cornerstone of prevention. Administer Pneumococcal vaccines (PCV15/20, PPSV23), Meningococcal vaccines (MenACWY, MenB), and Haemophilus influenzae type b (Hib) vaccine according to age and risk guidelines. Close contacts of patients with N. meningitidis should receive chemoprophylaxis (e.g., Ciprofloxacin 500 mg PO single dose, or Rifampin 600 mg PO BID for 2 days).
Overall mortality in adults is ~15-20%. S. pneumoniae carries a higher mortality (20-30%) compared to N. meningitidis (10%). Up to 30% of survivors suffer significant sequelae, including deafness, paresis, or cognitive impairment.